Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform

• Published in: Clinical pharmacology in drug development Vol. 13; no. 9; pp. 985 - 999
• Main Authors: Lennernäs, Hans, Brisander, Magnus, Liljebris, Charlotta, Jesson, Gérald, Andersson, Per
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2024
• Subjects: absorption; Administration, Oral; Adult; amorphous solid dispersion; Bioavailability; bioequivalence; Biological Availability; Cross-Over Studies; dasatinib; Dasatinib - administration & dosage; Dasatinib - pharmacokinetics; Drug Compounding; drug delivery; Female; Humans; Inhibitor drugs; Kinases; Male; Nanoparticles; protein kinase inhibitors; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - blood; Protein Kinase Inhibitors - pharmacokinetics; Solubility; sorafenib; Sorafenib - administration & dosage; Sorafenib - pharmacokinetics; Tablets; Therapeutic Equivalency; tyrosine kinase inhibitors; Young Adult; tyrosine kinase inhibitors; dasatinib; sorafenib; absorption; bioavailability; protein kinase inhibitors; drug delivery; bioequivalence; amorphous solid dispersion
• ISSN: 2160-763X; 2160-7648; 2160-7648
• DOI: 10.1002/cpdd.1416

Despite clinical advances with protein kinase inhibitors (PKIs), oral administration of many PKIs is associated with highly variable plasma exposure and a narrow therapeutic window. We developed a novel hybrid nanoparticle‐amorphous solid dispersion (ASD) technology platform consisting of an amorphous PKI embedded in a polymer matrix. The technology was used to manufacture immediate‐release formulations of 2 tyrosine kinase inhibitors (TKIs), dasatinib and sorafenib. Our primary objective was to improve the absorption properties and reduce the pharmacokinetic (PK) variability of each TKI. The PKs of XS004 (dasatinib‐ASD, 100 mg tablet) and XS005 (sorafenib‐ASD, 2 × 50 mg capsules) were compared with their crystalline formulated reference drugs (140 mg of dasatinib‐reference and 200 mg of sorafenib‐reference). The in vitro biopharmaceutics of dasatinib‐ASD and XS005‐granulate showed sustained increased solubility in the pH range 1.2‐8.0 compared to their crystalline references. In vivo, XS004 was bioequivalent at a 30% lower dose and showed increased absorption and bioavailability, with 2.1‐4.8 times lower intra‐ and intersubject variability compared to the reference. XS005 had an increased absorption and bioavailability of 45% and 2.2‐2.8 times lower variability, respectively, but it was not bioequivalent at the investigated dose level. Taken together, the formulation platform is suited to generate improved PKI formulations with consistent bioavailability and a reduced pH‐dependent absorption process.